Advances in Biomarker Research in Parkinson’s Disease

Current Neurology and Neuroscience Reports

Volumn 16, Issue 1, 2016, Pages 1-8

  Mehta, Shyamal H ^a   Adler, Charles H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biomarkers; Dopaminergic imaging; Parkinson s disease; Transcranial ultrasound; synuclein

Indexed keywords

6 FLUORODOPA F 18; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; DIHYDROTETRABENAZINE C 13; DJ 1 PROTEIN; IOMETOPANE I 123; RADIOPHARMACEUTICAL AGENT; TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; URIC ACID; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; COMORBIDITY; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOSMIA; INCIDENTAL LEWY BODY DISEASE; METABOLOMICS; ORAL BIOPSY; PARASOMNIA; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NIGROSTRIATAL DOPAMINERGIC NERVE CELL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEOMICS; REPRODUCIBILITY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBMANDIBULAR GLAND BIOPSY; URIC ACID BLOOD LEVEL; WESTERN BLOTTING; EARLY DIAGNOSIS; NEUROIMAGING; REM SLEEP BEHAVIOR DISORDER;

BIOMARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; METABOLOMICS; NEUROIMAGING; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER;

EID: 84952039556     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0607-4     Document Type: Review

References (57)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.
2. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of Parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt 4):861–70.
3. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83(5):406–12.
4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95.
5. Fox N, Growdon JH. Biomarkers and surrogates. NeuroRx. 2004;1(2):181.
6. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson’s disease. Parkinsonism Relat Disord. 2014;20 Suppl 1:S99–S103.
7. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6.
8. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95(4):629–635.
9. Stern MB, Siderowf A. Parkinson’s at risk syndrome: can Parkinson’s disease be predicted? Mov Disord. 2010;25 Suppl 1:S89–93.
10. Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol. 2013;20(1):102–8.
11. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56(2):173–81.
12. Driver-Dunckley E, Adler CH, Hentz JG, et al. Olfactory dysfunction in incidental Lewy body disease and Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(11):1260–2.
13. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010;25(5):642–6.
14. Katzenschlager R, Lees AJ. Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol. 2004;17(4):417–23.
15. Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical Parkinsonian syndromes. Acta Neurol Scand. 1995;91(4):247–50.
16. Postuma RB, Gagnon JF, Rompre S, Montplaisir JY. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology. 2010;74(3):239–44.
17. Postuma RB, Gagnon J-F, Bertrand J-A, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104–13. This paper presents data on conversion rates of a prospective cohort of RBD patients and other clinical risk factors to neurodegenerative disease over a 10 year follow-up period.
18. Pont-Sunyer C, Iranzo A, Gaig C, et al. Sleep disorders in Parkinsonian and nonparkinsonian LRRK2 mutation carriers. PLoS One. 2015;10(7), e0132368.
19. Chahine LM, Stern MB. Diagnostic markers for Parkinson’s disease. Curr Opin Neurol. 2011;24(4):309–17.
20. Schapira AH. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 2013;26(4):395–400.
21. Morgan JC, Mehta SH, Sethi KD. Biomarkers in Parkinson’s disease. Curr Neurol Neurosci Rep. 2010;10(6):423–30.
22. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with Ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101.
23. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived Neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59(3):459–66.
24. Perlmutter JS, Norris SA. Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol. 2014;76(6):769–83. This is a very elegant review and discussion of state of radiotracer imaging in Parkinson's disease both from a clinical and research perspective.
25. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–508.
26. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology. 1995;45(1):182–4.
27. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov Disord. 2005;20(3):383–5.
28. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol. 2011;68(7):932–7.
29. Stockner H, Iranzo A, Seppi K, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord. 2009;24(13):1906–9.
30. Iwanami M, Miyamoto T, Miyamoto M, Hirata K, Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med. 2010;11(4):361–5.
31. Pilotto A, Yilmaz R, Berg D. Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism. Curr Neurol Neurosci Rep. 2015;15(7):43. This paper reviews the growing evidence of TCUS studies in patients with parkinsonism and their ability to distinguish PD from atypical parkinsonism.
32. van de Loo S, Walter U, Behnke S, et al. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(10):1087–92.
33. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol. 2013;20(1):16–34.
34. Shi M, Zabetian CP, Hancock AM, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett. 2010;480(1):78–82.
35. Lin X, Cook TJ, Zabetian CP, et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2012;2:954.
36. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol. 1996;144(5):480–4.
37. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797–800.
38. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716–23.
39. Simon KC, Eberly S, Gao X, et al. Mendelian randomization of serum urate and Parkinson disease progression. Ann Neurol. 2014;76(6):862–8.
40. Schwarzschild MA, Ascherio A, Beal MF, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141–50. A large safety study showing the ability of inosine to raise urate levels in patients with PD. This has led to a larger study to assess the disease modifying potential of inosine.
41. Valdes AM, Glass D, Spector TD. Omics technologies and the study of human ageing. Nat Rev Genet. 2013;14(9):601–7.
42. Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson’s disease by metabolomic technologies. J Neurol Neurosurg Psychiatry. 2015.
43. Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L. 3-hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov Disord. 2013;28(12):1653–60.
44. Zetterberg H, Petzold M, Magdalinou N. Cerebrospinal fluid alpha-synuclein levels in Parkinson's disease—changed or unchanged? Eur J Neurol. 2014;21(3):365–7.
45. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70(10):1277–87.
46. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10(3):230–40.
47. Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015;84(1):57–63. This is a unique propspective study of CSF biomarkers which showed higher CSF α-synuclein levels were associated with a faster progression of motor symptoms and cognitive decline over 2 years.
48. Alves G, Lange J, Blennow K, et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82(20):1784–90.
49. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–61.
50. Schneider SA, Boettner M, Alexoudi A, Zorenkov D, Deuschl G, Wedel T. Can we use peripheral tissue biopsies to diagnose Parkinson’s disease? A review of the literature. Eur J Neurol. 2015.
51. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–39.
52. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119(6):689–702. This paper describes the distribution of phos-α-synuclein in the different organs in the body and led to the finding of submandibular gland having higher concentrations of phos-α-synuclein in Lewy body diseases.
53. Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol. 2013;72(2):130–6.
54. Adler CH, Dugger BN, Hinni ML, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology. 2014;82(10):858–64.
55. Beach TG, White 3rd CL, Hladik CL, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 2009;117(2):169–74.
56. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol. 2010;119(6):703–13.
57. Campbell MC, Koller JM, Snyder AZ, Buddhala C, Kotzbauer PT, Perlmutter JS. CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology. 2015;84(24):2413–21.